Naturalendo Tech Co., Ltd. (KOSDAQ:168330)
2,400.00
+30.00 (1.27%)
At close: Jun 5, 2026
Naturalendo Tech Revenue
Naturalendo Tech had revenue of 5.70B KRW in the quarter ending March 31, 2026, a decrease of -8.60%. This brings the company's revenue in the last twelve months to 21.69B, down -6.78% year-over-year. In the year 2025, Naturalendo Tech had annual revenue of 22.23B, down -0.16%.
Revenue (ttm)
21.69B
Revenue Growth
-6.78%
P/S Ratio
3.49
Revenue / Employee
267.78M
Employees
81
Market Cap
75.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.23B | -36.68M | -0.16% |
| Dec 31, 2024 | 22.26B | 3.47B | 18.48% |
| Dec 31, 2023 | 18.79B | 4.84B | 34.69% |
| Dec 31, 2022 | 13.95B | -744.85M | -5.07% |
| Dec 31, 2021 | 14.70B | 1.45B | 10.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 128.76B |
| KoBioLabs | 71.21B |
| Choong Ang Vaccine Laboratory | 39.19B |
| BIO-FD&C | 18.85B |
| Ark Solutions | 17.95B |
| PanGen Biotech | 13.71B |
| TegoScience | 5.83B |
| EyeGene | 4.02B |